Roche Gets Recommendation for Use of Spinal Muscular Atrophy Treatment in Europe
By Joshua Kirby
Roche Holding AG said Friday that it received an approval
recommendation from a European Medicines Agency committee for
Evrysdi, its spinal muscular atrophy treatment.
The Swiss pharmaceutical company said the EMA's committee for
Medicinal Products for Human Use recommended the approval of
Evrysdi in patients aged two months and older diagnosed with SMA of
The recommendation was made under the accelerated assessment
pathway for medicines considered to be of major public interest for
public health, Roche said. A final decision from the EMA on the use
of the treatment in the European Union is expected within the next
two months, it added.
Write to Joshua Kirby at firstname.lastname@example.org;
(END) Dow Jones Newswires
February 26, 2021 06:58 ET (11:58 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.